Quantum Cyber N.V. (QUCY) Stock Price & Analysis
Quantum Cyber N.V. (QUCY) fell 2.86% to USD 2.04 as of June 9, 2026 at 23:57 UTC, according to Nexqual real-time market data.
QUCY last closed at USD 2.1; the session ranged USD 1.86–2.05 on volume of 1,831,722 shares. Market capitalization is $46.45M, with a 52-week range of USD 0.3–4.93 (NCM). Source: Nexqual, June 9, 2026 at 23:57 UTC.
Key Statistics (as of June 9, 2026 at 23:57 UTC)
| Price | USD 2.04 |
|---|---|
| Change | ▼ 2.86% (down) |
| Previous Close | USD 2.1 |
| Open | USD 2.02 |
| Day Range | USD 1.86 – 2.05 |
| 52-Week Range | USD 0.3 – 4.93 |
| Volume | 1,831,722 shares |
| Market Cap | $46.45M |
| Exchange | NCM |
Technical Analysis (QUCY)
Nexqual's technical model rates QUCY "BUY" based on 4 bullish and 2 bearish signals across 124 daily candles, as of June 9, 2026 at 23:57 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 49.23 (neutral) |
| vs SMA50 | Above (USD 1.32) |
| MACD | 0.26 (positive) |
Analyst Ratings (QUCY)
Wall Street analysts rate QUCY "None", per Nexqual as of June 9, 2026 at 23:57 UTC.
| Consensus Rating | None |
|---|---|
| Buy / Hold / Sell | 0 / 1 / 0 |
Earnings (QUCY)
Source: Nexqual, June 9, 2026 at 23:57 UTC.
Financials & Fundamentals (QUCY)
| Total Revenue | $537,080 |
|---|---|
| Gross Margin | +72.58% |
| Operating Margin | -2460.78% |
| Profit Margin | +0.00% |
| ROE | -447.97% |
| Debt / Equity | 2.76 |
| Current Ratio | 2.11 |
| Total Cash | $4.45M |
| Total Debt | $126,791 |
| Free Cash Flow | $-8.77M |
Source: Nexqual, June 9, 2026 at 23:57 UTC.
Financial Health Score (QUCY)
Nexqual rates Quantum Cyber N.V.'s overall financial health "Weak" across five dimensions, as of June 9, 2026 at 23:57 UTC.
| Growth | Critical — Revenue -40% YoY (annual), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $4M cash, no debt |
| Cash Flow | Weak — FCF negative: -$9M, burning cash |
| Efficiency | Critical — ROE -448%, ROA -94.3% |
Ownership (QUCY)
| Insider Ownership | +7.00% |
|---|---|
| Institutional Ownership | +1.55% |
| Shares Outstanding | 22.77M |
| Float | 12.71M |
| Short % of Float | +78.42% |
Source: Nexqual, June 9, 2026 at 23:57 UTC.
Leadership (QUCY)
Quantum Cyber N.V. is led by David Elliot Lazar (age 34), CEO & Director, per Nexqual as of June 9, 2026 at 23:57 UTC.
| CEO & Director | David Elliot Lazar (age 34) |
|---|---|
| Chief Operating Officer | Christopher Von Toerne P.M.P. (age 53) |
Major Backers & Investors (QUCY)
Notable institutional backers of Quantum Cyber N.V. include UBS Group AG, Xtx Topco Ltd, Steward Partners Investment Advisory, LLC, according to Nexqual as of June 9, 2026 at 23:57 UTC.
Active Investors
| Investor | Stake |
|---|---|
| UBS Group AG | 0.38% |
| Xtx Topco Ltd | 0.28% |
| Steward Partners Investment Advisory, LLC | 0.13% |
| Virtu Financial LLC | 0.13% |
Source: Nexqual, June 9, 2026 at 23:57 UTC.
From Quantum Cyber N.V.'s Latest SEC 10-K Filing (filed 2026-03-31)
Key Strengths & Strategy (as disclosed to the SEC)
- In March 2025, we acquired a license from Liquid Bioscience, Inc. to access a portfolio of novel mRNA biomarkers and AI developed proprietary algorithm, for the non-invasive detection of pancreatic cancer with a blood test.
- Our approach integrates proprietary, validated biomarkers with reliable diagnostic tools to optimize accuracy and applicability.
- In the analysis, the biomarkers coupled with the proprietary algorithm developed by Liquid, achieved overall sensitivity of 95% and a 98% specificity for the detection of pancreatic cancer.
-   General   Historically, we have developed and sold in-vitro diagnostic ("IVD") tests for the early detection of cancer.
Partnerships
- Through our agreement with the Université de Sherbrooke, we obtained an exclusive, unilateral option to acquire a license for the UdeS Biomarkers.
- Enabling earlier detection of these diseases allows for earlier and better therapy for affected individuals.   1     Pancreatic Cancer Screening Tests   In March 2025, the Company entered into an Agreement with Liquid Biosciences.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| QTEX | QTREX Quantum Ltd. | USD 1.6 | ▲ 12.68% |
| HCWB | HCW Biologics Inc. | USD 1.18 | ▼ 27.61% |
| AIIO | Robo.ai Inc. | USD 2.83 | ▼ 3.74% |
| SPRC | SciSparc Ltd. | USD 9.31 | ▼ 18.62% |
| LASE | Laser Photonics Corporation | USD 2.51 | ▼ 19.03% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 9, 2026 at 23:57 UTC. This page is informational and not investment advice.